General Information of Drug (ID: DMOGV9F)

Drug Name
NSC-2113 Drug Info
Synonyms
1,4-Diethoxybenzene; 122-95-2; Benzene, 1,4-diethoxy-; p-Diethoxybenzene; Hydroquinone diethyl ether; Benzene, p-diethoxy-; NSC-2113; 1,4-diethoxy-benzen; UNII-C6Y51501JB; CHEMBL219898; VWGNFIQXBYRDCH-UHFFFAOYSA-N; C6Y51501JB; Benzene,4-diethoxy-; NSC2113; NSC 2113; EINECS 204-585-5; 1,4-diethoxybenzol; hydroquinonedlethylether; ACMC-209ans; AI3-09458; AC1Q37UB; AC1L26YB; KSC174M8J; SCHEMBL124015; Benzene, p-diethoxy- (8CI); Jsp001542; DTXSID9059549; CTK0H4684; KS-00000WIN; MolPort-001-759-994; ZINC394919; NSC68808; SBB060362
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
67150
CAS Number
CAS 122-95-2
TTD Drug ID
DMOGV9F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ARQ 761 DMH5CAL Pancreatic cancer 2C10 Phase 2 [2]
Coenzyme Q10 analog DMO0VGH Huntington disease 8A01.10 Phase 2 [3]
BioE-743 DM7PT8R Leigh syndrome 5C53.24 Phase 2 [4]
Flavin-Adenine Dinucleotide DM5S4GK Discovery agent N.A. Investigative [5]
NSC-645808 DMMBAR3 Discovery agent N.A. Investigative [1]
NSC-106080 DMR6P9S Discovery agent N.A. Investigative [6]
NSC-99528 DMXZAIG Discovery agent N.A. Investigative [6]
NSC-354279 DMVL51I Discovery agent N.A. Investigative [1]
Duroquinone DML7YPS Discovery agent N.A. Investigative [5]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate DMJQTIK Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Quinone reductase 1 (NQO1) TT8XK6L NQO1_HUMAN Inhibitor [1]

References

1 In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
7 Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.